NEW YORK (GenomeWeb News) - Illumina’s stock rose nearly 16 percent, to $70.02, in afternoon trading after this morning’s news that the company will settle its longstanding patent-infringement litigation with Affymetrix without admitting liability and without paying royalties.
 
Under the terms of the settlement, Illumina will pay Affy $90 million and the companies agreed to a covenant not to sue each other in the future.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.